Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Assessing prognostic value of early tumor shrinkage and depth of response in first-line therapy for patients with advanced unresectable pancreatic cancer

Characteristics

Patients

n = 90

 

n

%

Age, years

 Median

59

 Range

38–89

 < 65

63

70

 ≥ 65

27

30

Sex

 Male

57

63.3

 Female

33

36.7

ECOG performance status

 0

44

48.9

 1

27

30.0

 2

19

21.1

Histology

 Adenocarcinoma

89

98.9

 Adenosquamous carcinoma

1

1.1

Tumor site

 Head-uncinate process

41

45.6

 Body-tail

47

52.2

 Multifocal

2

2.2

Synchronous disease

 Yes

47

64.4

 No

26

35.6

No. of metastatic sites

 1–2

61

83.6

 3–4

12

16.4

Localization of metastasis

 Liver

61

67.8

 Peritoneal

13

14.4

 Lung

6

6.7

 Bones

2

2.2

 Local recurrence (including regional lymph node metastases)

17

18.9

Previous treatments

 Radical surgery

43

47.8

 Adjuvant chemotherapy

24

26.7

Ca19.9 (KU/L)

 ≤ ULN

15

16.7

 > ULN

75

83.3

Biliary stent

 Yes

3

3.3

 No

87

96.7

HDL-C (mmol/L)

 > 0.9

77

85.6

 ≤ 0.9

13

14.4

  1. Ca19.9 carbohydrate antigen 19–9, DpR depth of response, ECOG Eastern Cooperative Oncology Group, ETS early tumour shrinkage, IPMN intraductal papillary mucinous neoplasm, ULN upper limit of normal, HDL-C High-density lipoprotein cholesterol